Mengis Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.48M | Sell |
40,858
-375
| -0.9% | -$21.9K | 0.43% | 66 |
|
|
2025
Q4 | $2.22M | Sell |
41,233
-6,201
| -13% | -$298K | 0.39% | 65 |
|
|
2025
Q3 | $2.14M | Sell |
47,434
-9,349
| -16% | -$437K | 0.42% | 64 |
|
|
2025
Q2 | $2.63M | Sell |
56,783
-6,325
| -10% | -$310K | 0.56% | 48 |
|
|
2025
Q1 | $3.85M | Sell |
63,108
-425
| -0.7% | -$24.8K | 0.8% | 38 |
|
|
2024
Q4 | $3.59M | Sell |
63,533
-1,640
| -3% | -$91.6K | 0.73% | 35 |
|
|
2024
Q3 | $3.37M | Sell |
65,173
-9,535
| -13% | -$447K | 0.66% | 42 |
|
|
2024
Q2 | $3.1M | Sell |
74,708
-7,224
| -9% | -$323K | 0.63% | 41 |
|
|
2024
Q1 | $4.44M | Sell |
81,932
-44,525
| -35% | -$2.27M | 0.69% | 35 |
|
|
2023
Q4 | $6.49M | Sell |
126,457
-5,598
| -4% | -$294K | 1.22% | 21 |
|
|
2023
Q3 | $7.66M | Sell |
132,055
-1,414
| -1% | -$86.6K | 1.59% | 16 |
|
|
2023
Q2 | $8.54M | Sell |
133,469
-8,775
| -6% | -$588K | 1.7% | 13 |
|
|
2023
Q1 | $9.86M | Sell |
142,244
-4,410
| -3% | -$311K | 2.08% | 9 |
|
|
2022
Q4 | $10.6M | Sell |
146,654
-1,650
| -1% | -$124K | 2.3% | 8 |
|
|
2022
Q3 | $10.5M | Sell |
148,304
-5,622
| -4% | -$408K | 2.5% | 7 |
|
|
2022
Q2 | $11.9M | Sell |
153,926
-12,359
| -7% | -$941K | 2.6% | 6 |
|
|
2022
Q1 | $12.1M | Buy |
166,285
+235
| +0.1% | +$15.8K | 2.33% | 7 |
|
|
2021
Q4 | $10.4M | Buy |
166,050
+2,115
| +1% | +$124K | 1.94% | 11 |
|
|
2021
Q3 | $9.7M | Buy |
163,935
+302
| +0.2% | +$19.9K | 2.04% | 10 |
|
|
2021
Q2 | $10.9M | Buy |
163,633
+16,139
| +11% | +$1.05M | 2.27% | 8 |
|
|
2021
Q1 | $9.31M | Buy |
147,494
+7,493
| +5% | +$466K | 2.06% | 9 |
|
|
2020
Q4 | $8.68M | Buy |
140,001
+12,366
| +10% | +$760K | 2.11% | 9 |
|
|
2020
Q3 | $7.7M | Buy |
127,635
+3,976
| +3% | +$239K | 2.11% | 9 |
|
|
2020
Q2 | $7.27M | Buy |
123,659
+12,384
| +11% | +$741K | 2.16% | 9 |
|
|
2020
Q1 | $6.2M | Buy |
111,275
+3,384
| +3% | +$207K | 2.12% | 9 |
|
|
2019
Q4 | $6.92M | Buy |
107,891
+38,972
| +57% | +$2.23M | 1.91% | 9 |
|
|
2019
Q3 | $3.49M | Buy |
68,919
+8,307
| +14% | +$390K | 1.04% | 28 |
|
|
2019
Q2 | $2.75M | Buy |
60,612
+16,681
| +38% | +$777K | 0.84% | 38 |
|
|
2019
Q1 | $2.1M | Buy |
43,931
+768
| +2% | +$38.3K | 1.17% | 29 |
|
|
2018
Q4 | $2.24M | Sell |
43,163
-2,374
| -5% | -$128K | 1.42% | 24 |
|
|
2018
Q3 | $2.83M | Sell |
45,537
-695
| -2% | -$41.2K | 1.55% | 19 |
|
|
2018
Q2 | $2.56M | Sell |
46,232
-2,944
| -6% | -$159K | 1.51% | 21 |
|
|
2018
Q1 | $3.11M | Sell |
49,176
-195
| -0.4% | -$12.5K | 1.86% | 15 |
|
|
2017
Q4 | $3.02M | Buy |
49,371
+484
| +1% | +$30.3K | 1.83% | 16 |
|
|
2017
Q3 | $3.12M | Sell |
48,887
-1,949
| -4% | -$114K | 2.09% | 15 |
|
|
2017
Q2 | $2.83M | Buy |
50,836
+1,002
| +2% | +$54.5K | 2.01% | 16 |
|
|
2017
Q1 | $2.71M | Buy |
49,834
+1,812
| +4% | +$99.4K | 1.98% | 15 |
|
|
2016
Q4 | $2.81M | Buy |
48,022
+2,001
| +4% | +$109K | 2.23% | 12 |
|
|
2016
Q3 | $2.48M | Buy |
46,021
+1,502
| +3% | +$96.5K | 2.07% | 15 |
|
|
2016
Q2 | $3.27M | Buy |
44,519
+1,401
| +3% | +$99K | 2.89% | 8 |
|
|
2016
Q1 | $2.75M | Buy |
43,118
+14,995
| +53% | +$946K | 2.54% | 10 |
|
|
2015
Q4 | $1.93M | Sell |
28,123
-27
| -0.1% | -$1.78K | 1.69% | 21 |
|
|
2015
Q3 | $1.67M | Sell |
28,150
-2,695
| -9% | -$171K | 1.55% | 24 |
|
|
2015
Q2 | $2.05M | Buy |
30,845
+1,305
| +4% | +$86K | 1.72% | 21 |
|
|
2015
Q1 | $1.91M | Buy |
29,540
+606
| +2% | +$37.9K | 1.66% | 20 |
|
|
2014
Q4 | $1.71M | Buy |
+28,934
| New | +$1.63M | 1.65% | 21 |
|
Other funds holding BMY
VCM
VPM
Mengis Capital Management's BMY Position: Q1 2026 in Review
Mengis Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 0.91% in Q1 2026, selling an estimated $21.9K and leaving 40,858 shares worth $2.48M. The position accounts for 0.43% of the portfolio, ranked #66.
Mengis Capital Management first reported a position in BMY in Q4 2014 and has held it in 46 quarters since. The position peaked at $12.1M in Q1 2022. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Mengis Capital Management held 40,858 shares of Bristol-Myers Squibb worth $2.48M as of Q1 2026.
- Mengis Capital Management sold 375 Bristol-Myers Squibb shares in Q1 2026, an estimated $21.9K.
- Bristol-Myers Squibb made up 0.43% of Mengis Capital Management's portfolio in Q1 2026, its #66 holding.
- Mengis Capital Management first reported a position in Bristol-Myers Squibb in Q4 2014 and has held it in 46 quarters since.
- Mengis Capital Management's Bristol-Myers Squibb position peaked at $12.1M in Q1 2022.
- 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Mengis Capital Management's 13F filing for Q1 2026, filed 12 May 2026.